Mepolizumab Compared with Placebo in Subjects with EGPA Receiving Standard of Care Therapy: MIRRA

Study Findings: This was the first clinical trial exclusively performed in patients with EGPA. Compared to prednisone alone, patients with EGPA receiving mepolizumab had more weeks in remission and were able to taper prednisone to lower doses. View Publication.

ClinicalTrials.gov ID: NCT02020889

Study Dates: 2014-2017

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA)